PUBLISHER: IMARC | PRODUCT CODE: 1541310
PUBLISHER: IMARC | PRODUCT CODE: 1541310
The global HPV testing and PAP test market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth. In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor. This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global HPV testing and PAP test market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type, product, application and end user.
HPV Test
Pap Test
Co-testing
Instruments
Consumables
Services
Cervical Cancer Screening
Vaginal Cancer Screening
Hospitals and Clinics
Laboratories
Diagnostic Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.